Title Credit Type Event date Cost
Escape Room Experience: Individualizing Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Clinical Insights into Psoriasis in Patients of Color: Bringing New Data to Light
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes
    • 1.50 AAFP
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Participation
 Enduring $0.00
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
    • 0.75 ACPE Pharmacy
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 ANCC
    • 0.75 Participation
 Enduring $0.00
According to the Patient: Alopecia Areata in Adolescence
    • 1.00 AAPA Category I CME
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk: A Paradigm Shift
    • 1.50 CDE
    • 1.50 ACPE Pharmacy
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 ANCC
    • 1.50 Participation
 Enduring $0.00
Expanding the Therapeutic “AHR”senal for Pediatric Atopic Dermatitis
    • 1.00 AAPA Category I CME
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Psoriasis in Skin of Color Unplugged: Addressing the Barriers to Patient Care and Relief
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
Advances in Non-Steroidal Topicals: PDE-4 Inhibitors for Seborrheic Dermatitis and Beyond
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 ANCC
    • 0.75 Participation
 Enduring $0.00
Ace the Case Challenge Series: Exploring Novel Strategies for LDL-C Combination Therapy to Decrease ASCVD Risk
    • 0.75 ACPE Pharmacy
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 ANCC
    • 0.75 Participation
 Enduring $0.00
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
    • 1.50 CDE
    • 1.50 ACPE Pharmacy
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 ANCC
    • 1.50 Participation
 Enduring $0.00
Ace the Case Challenge Series: The Intersection of MASH and Cardiometabolic Risk
    • 0.50 CDE
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 ANCC
    • 0.50 Participation
 Enduring $0.00
The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes
    • 0.50 ACPE Pharmacy
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 ANCC
    • 0.50 Participation
 Enduring $0.00
A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches
    • 1.00 AANP
    • 1.00 AAPA Category I CME
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00
The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes
    • 1.00 ACPE Pharmacy
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 ANCC
    • 1.00 Participation
 Enduring $0.00

Pages